NEWARK, DE — MyStart Health LLC expanded its telehealth infrastructure ahead of the 2026 weight-management season, positioning the Delaware-based platform to handle rising demand for medically supervised programs using compounded GLP-1 medications, including semaglutide and tirzepatide.
The company connects patients in eligible states with board-certified physicians who evaluate candidacy for compounded GLP-1 prescriptions through virtual consultations. MyStart Health said interest typically climbs from late November through early January as individuals begin planning health goals and seek support before holiday-related dietary challenges and New Year’s resolutions.
MyStart Health’s expanded capacity is designed to reduce barriers that often limit access to medical weight-loss programs, including insurance requirements, long clinic wait times and geographic constraints. The platform’s membership model includes virtual clinical evaluations, ongoing provider oversight, patient-support tools and coordinated pharmacy fulfillment for compounded medications when prescribed.
Monthly pricing starts at $179 for compounded semaglutide programs, while three-month tirzepatide programs are available for under $300 per month, subject to patient eligibility, prescription approval and evolving state and federal compounding regulations.
The company said its expanded telehealth model offers same-day consultation availability, faster intake processing and streamlined prescription coordination with licensed compounding pharmacies. Services are provided through a nationwide network of more than 600 U.S. physicians.
Compounded GLP-1 drugs are prepared by licensed pharmacies but are not FDA-approved, and their availability varies by state based on shifting regulatory guidance. Providers determine eligibility on a case-by-case basis and may require video consultations to address safety considerations before prescribing medication.
MyStart Health emphasized that prescribing decisions are made solely by independent clinicians who assess medical histories, contraindications and overall suitability for GLP-1 therapy. Patients who do not qualify may be eligible for refunds under the company’s posted policy.
The company said it continues to see strong consumer interest in telehealth weight-management platforms, driven by convenience, transparent pricing and broad access. MyStart Health noted that virtual programs can offer more scheduling flexibility than traditional clinics and allow patients to receive ongoing medical guidance throughout treatment.
Patients remain responsible for understanding the regulatory distinctions between compounded and FDA-approved GLP-1 medications, and MyStart Health said its providers discuss safety considerations, medication differences and alternative treatment options during evaluations.
MyStart Health maintains HIPAA-compliant systems to protect patient information and provides cancellation options through its customer support channels.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.